Good pt Fred . FDA approval will likely be a " Sell the news " event until the first set of warrants are exercised .
So we have to see how the market takes this .
UNCY has to pay Shilpa $10m on delivery of first batch of OLC ( Renazorb ) IIRC and won't have Medicare coverage until TDAPA is completed ...so they will likely be handing out a lot of free samples to test in clinic responses and burning thru cash on hand.
Typically biotech raise $ on FDA approval ...so this first warrant is basically fore filling that function ...its just how people trade around this .
For me it comes down to the deal they make with Fresenius and DaVita . That determines if OLC gets onto the clinic shelves , if the nephrologists at these clinics actively encourage patients to try OLC ...how much supply UNCY is willing to put out there as free samples etc.
As I've mentioned before .
I've been on statins since they were first approved ( Mevacor )
These were low intensity statins until Lipitor came along ( a high intensity statin )
When Lipitor came out I was handed free samples all over the place . First my Cardiologist , then my local MD and later even my wife from a dialysis clinic .
" Hey you're already on a statin ...this is the latest and it works better "..etc
After 3 mths of free Lipitor ...I never went back
I need to do more work on the warrants
Thx for mentioning
Kiwi
PS. Most CEO's are cheerleaders IMHO
Market Data 
Markets 
AI
